NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
First intramuscular administration in the U.S. space programIn the past, the only kind of medicines used for symptomatic treatment of space motion sickness (SMS) in space had been oral, transdermal, or suppositories. This paper describes the effect of the first intramuscular (IM) administration of Phenergan (50-mg in single dose) on SMS in one subject who exhibited grade-3 symptoms and signs which persisted unabated throughout the first and the second flight days aboard the Space Shuttle. Thirty minutes after the injection, the subject had completely recovered. His symptoms were gone, his appetite was back, and he had no recurrences for the remainder of the flight. Since that experiment, intramuscular injections have been given nine more times on subsequent flights, with similar results.
Document ID
19930033537
Document Type
Reprint (Version printed in journal)
Authors
Bagian, James P. (NASA Johnson Space Center Houston, TX, United States)
Date Acquired
August 15, 2013
Publication Date
October 1, 1991
Publication Information
Publication: Journal of Clinical Pharmacology
Volume: 31
Issue: 10
ISSN: 0091-2700
Subject Category
AEROSPACE MEDICINE
Distribution Limits
Public
Copyright
Other